Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than <i>Clostridium difficile</i> infection: a systematic review and meta-analysis
Jessica Green, Jessica A. Davis, Michael Berk, Christopher Hair, Amy Loughman, David Castle, Eugene Athan, Andrew A. Nierenberg, John F. Cryan, Felice N. Jacka, Wolfgang Marx
Abstract
= .739). Hepatic disorders, metabolic syndrome, and antibiotic-resistant organisms were conditions with emerging data on FMT. Serious adverse events (AE) were more often reported in control group participants (n = 43) compared with FMT group participants (n = 26). There were similar rates of mild to moderate AE in both groups. Preliminary data suggest that FMT is a potentially safe, well-tolerated and efficacious treatment for certain conditions other than CDI, with evidence for active UC being the most compelling.
Topics & Concepts
Fecal bacteriotherapyInternal medicineClostridium difficileMedicineIrritable bowel syndromeMeta-analysisMicrobiomeMEDLINEGastroenterologyAdverse effectTransplantationAntibioticsBioinformaticsBiologyMicrobiologyBiochemistryClostridium difficile and Clostridium perfringens researchGastrointestinal motility and disordersGut microbiota and health